Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MCF7 Tivantinib
0.031623
MET
RTK
 0.9387 0.00325
MCF7 Tivantinib
0.1
MET
RTK
 0.6729 0.02472
MCF7 Tivantinib
0.31623
MET
RTK
 0.2140 0.11704
MCF7 Tivantinib
1.0
MET
RTK
 -0.0087 0.25609
MCF7 Tivantinib
3.1623
MET
RTK
 0.0392 0.24788
MCF7 Tivantinib
10.0
MET
RTK
 -0.0512 0.23320
MCF7 Cediranib
0.001
VEGFR/cKIT
RTK
 1.0013 -0.00012
MCF7 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0519 -0.00143
MCF7 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0466 -0.00064
MCF7 Cediranib
0.031623
VEGFR/cKIT
RTK
 1.0041 -0.00071
MCF7 Cediranib
0.1
VEGFR/cKIT
RTK
 1.0382 -0.00225
MCF7 Cediranib
0.31623
VEGFR/cKIT
RTK
 0.9975 0.00032
MCF7 Cediranib
1.0
VEGFR/cKIT
RTK
 0.9255 0.00066
MCF7 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.7736 0.00746
MCF7 Cediranib
10.0
VEGFR/cKIT
RTK
 0.1149 0.16822
MCF7 Cabozantinib
0.001
VEGFR2/MET
RTK
 1.0100 0.00359
MCF7 Cabozantinib
0.0031623
VEGFR2/MET
RTK
 1.0258 -0.00025
MCF7 Cabozantinib
0.01
VEGFR2/MET
RTK
 0.9893 0.00152
MCF7 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0228 0.00136
MCF7 Cabozantinib
0.1
VEGFR2/MET
RTK
 0.9964 0.00101
MCF7 Cabozantinib
0.31623
VEGFR2/MET
RTK
 0.9530 0.00287
MCF7 Cabozantinib
1.0
VEGFR2/MET
RTK
 0.9636 0.00456
MCF7 Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.7384 0.01503
MCF7 Cabozantinib
10.0
VEGFR2/MET
RTK
 -0.0993 0.24217
MDA-MB-231 Abemaciclib
0.001
CDK4/6
Cell cycle
 0.9195 0.00637